The P-III trial (AXLerate-OC) evaluating the safety and efficacy of batiraxcept in 366 patients with Pt-resistant ovarian cancer
The trial failed to meet its 1EPs of PFS in the pre-specified subset of patients naïve to prior bevacizumab treatment & did not show any difference b/w two arms in the overall population (incl. patients previously treated with bevacizumab). The company seeks to determine the next steps in the development of batiraxcept & will continue to assess the complete dataset
In the bevacizumab-naïve & overall population, m-PFS was 5.4 & 5.1mos. in batiraxcept + paclitaxel arm vs 5.4 & 5.5mos. in paclitaxel. The safety profile was consistent with prior studies with no new safety signals
Ref: Aravive | Image: Aravive
Related News:- Aravive Reports Updated Results of Batiraxcept in the P-Ib Study for the Treatment of Clear Cell Renal Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
